Celgene Amends Complaint In Thalomid Spat
Pharmaceutical company Celgene Corp. has launched another attack in its ongoing crusade to protect cancer drug Thalomid from generic competition, filing an amended complaint in the pending patent litigation against generic...To view the full article, register now.
Already a subscriber? Click here to view full article